Managing cardiovascular risk in patients with metabolic syndrome (Q36563115)

14 August 2017

1 reference

title

Managing cardiovascular risk in patients with metabolic syndrome (English)

1 reference

14 August 2017

1 reference

Jean-Pierre Bassand

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

8 Suppl 1

1 reference

14 August 2017

page(s)

S7-14

1 reference

The metabolic syndrome: prevalence in worldwide populations

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Components of the "metabolic syndrome" and incidence of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Correlation between cardiovascular disease and diabetes mellitus: current concepts

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

C-reactive protein levels and outcomes after statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Diet composition and the metabolic syndrome: what is the optimal fat intake?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Ph

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

A cardioprotective "polypill"? Independent and additive benefits of lifestyle modification

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Atenolol in hypertension: is it a wise choice?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Long-term metabolic effects of antihypertensive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Metabolic manifestations of low-dose diuretics

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Exercise-induced changes in coagulation and fibrinolysis in healthy populations and patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980003-7

7 January 2021

10.1016/S1098-3597(06)80003-7

Identifiers

DOI

1 reference

14 August 2017

1 reference